A practical guide to the management of hypertension in renal transplant recipients

Ali J. Olyaei, Angelo M DeMattos, William M. Bennett

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Hypertension as well as hypotension can be harmful to a newly transplanted renal allograft. Elevated blood pressure is also a major risk factor for cardiovascular death, which is a frequent occurrence despite successful renal transplantation. Renal artery stenosis, immunosuppressive drugs, chronic rejection, retained native kidneys, and excessive extracellular fluid volume may all contribute to post-transplant hypertension. Antihypertensive agents are widely used in the management of post-transplant hypertension. Careful clinical judgement and knowledge of the pharmacology, pharmacodynamics, pharmacokinetics, adverse drug reaction profiles, potential contraindications, and drug-drug interactions of antihypertensive agents are important when therapy with antihypertensive drugs is initiated in renal transplant recipients. Since blood pressure elevation in any individual is determined by a large number of hormonal and neuronal systems, the effect of antihypertensive agents on the allograft should be considered a critical factor in the management of hypertension in renal transplant recipients. Most renal transplant recipients have other risk factors for premature cardiovascular death such as diabetes mellitus, hypercholesterolemia, insulin resistance, obesity, left ventricular hypertrophy and ischaemic heart disease. Initial antihypertensive therapy should be tailored individually according to the patient's risk factors. A realistic therapeutic goal for blood pressure management in the initial postoperative state is a systolic blood pressure < 160 mmHg and a diastolic blood pressure < 90 mmHg with lower pressure targets becoming applicable late post transplantation.

Original languageEnglish (US)
Pages (from-to)1011-1027
Number of pages17
JournalDrugs
Volume58
Issue number6
StatePublished - 1999
Externally publishedYes

Fingerprint

Transplants
Renal Hypertension
Blood pressure
Antihypertensive Agents
Blood Pressure
Kidney
Allografts
Hypertension
Drug interactions
Pharmacodynamics
Pharmaceutical Preparations
Pharmacokinetics
Immunosuppressive Agents
Medical problems
Renal Artery Obstruction
Premature Mortality
Extracellular Fluid
Left Ventricular Hypertrophy
Transplant Recipients
Hypercholesterolemia

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

A practical guide to the management of hypertension in renal transplant recipients. / Olyaei, Ali J.; DeMattos, Angelo M; Bennett, William M.

In: Drugs, Vol. 58, No. 6, 1999, p. 1011-1027.

Research output: Contribution to journalArticle

Olyaei, Ali J. ; DeMattos, Angelo M ; Bennett, William M. / A practical guide to the management of hypertension in renal transplant recipients. In: Drugs. 1999 ; Vol. 58, No. 6. pp. 1011-1027.
@article{2a7ecaf848044c2da1a04b0ba55c5d78,
title = "A practical guide to the management of hypertension in renal transplant recipients",
abstract = "Hypertension as well as hypotension can be harmful to a newly transplanted renal allograft. Elevated blood pressure is also a major risk factor for cardiovascular death, which is a frequent occurrence despite successful renal transplantation. Renal artery stenosis, immunosuppressive drugs, chronic rejection, retained native kidneys, and excessive extracellular fluid volume may all contribute to post-transplant hypertension. Antihypertensive agents are widely used in the management of post-transplant hypertension. Careful clinical judgement and knowledge of the pharmacology, pharmacodynamics, pharmacokinetics, adverse drug reaction profiles, potential contraindications, and drug-drug interactions of antihypertensive agents are important when therapy with antihypertensive drugs is initiated in renal transplant recipients. Since blood pressure elevation in any individual is determined by a large number of hormonal and neuronal systems, the effect of antihypertensive agents on the allograft should be considered a critical factor in the management of hypertension in renal transplant recipients. Most renal transplant recipients have other risk factors for premature cardiovascular death such as diabetes mellitus, hypercholesterolemia, insulin resistance, obesity, left ventricular hypertrophy and ischaemic heart disease. Initial antihypertensive therapy should be tailored individually according to the patient's risk factors. A realistic therapeutic goal for blood pressure management in the initial postoperative state is a systolic blood pressure < 160 mmHg and a diastolic blood pressure < 90 mmHg with lower pressure targets becoming applicable late post transplantation.",
author = "Olyaei, {Ali J.} and DeMattos, {Angelo M} and Bennett, {William M.}",
year = "1999",
language = "English (US)",
volume = "58",
pages = "1011--1027",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - A practical guide to the management of hypertension in renal transplant recipients

AU - Olyaei, Ali J.

AU - DeMattos, Angelo M

AU - Bennett, William M.

PY - 1999

Y1 - 1999

N2 - Hypertension as well as hypotension can be harmful to a newly transplanted renal allograft. Elevated blood pressure is also a major risk factor for cardiovascular death, which is a frequent occurrence despite successful renal transplantation. Renal artery stenosis, immunosuppressive drugs, chronic rejection, retained native kidneys, and excessive extracellular fluid volume may all contribute to post-transplant hypertension. Antihypertensive agents are widely used in the management of post-transplant hypertension. Careful clinical judgement and knowledge of the pharmacology, pharmacodynamics, pharmacokinetics, adverse drug reaction profiles, potential contraindications, and drug-drug interactions of antihypertensive agents are important when therapy with antihypertensive drugs is initiated in renal transplant recipients. Since blood pressure elevation in any individual is determined by a large number of hormonal and neuronal systems, the effect of antihypertensive agents on the allograft should be considered a critical factor in the management of hypertension in renal transplant recipients. Most renal transplant recipients have other risk factors for premature cardiovascular death such as diabetes mellitus, hypercholesterolemia, insulin resistance, obesity, left ventricular hypertrophy and ischaemic heart disease. Initial antihypertensive therapy should be tailored individually according to the patient's risk factors. A realistic therapeutic goal for blood pressure management in the initial postoperative state is a systolic blood pressure < 160 mmHg and a diastolic blood pressure < 90 mmHg with lower pressure targets becoming applicable late post transplantation.

AB - Hypertension as well as hypotension can be harmful to a newly transplanted renal allograft. Elevated blood pressure is also a major risk factor for cardiovascular death, which is a frequent occurrence despite successful renal transplantation. Renal artery stenosis, immunosuppressive drugs, chronic rejection, retained native kidneys, and excessive extracellular fluid volume may all contribute to post-transplant hypertension. Antihypertensive agents are widely used in the management of post-transplant hypertension. Careful clinical judgement and knowledge of the pharmacology, pharmacodynamics, pharmacokinetics, adverse drug reaction profiles, potential contraindications, and drug-drug interactions of antihypertensive agents are important when therapy with antihypertensive drugs is initiated in renal transplant recipients. Since blood pressure elevation in any individual is determined by a large number of hormonal and neuronal systems, the effect of antihypertensive agents on the allograft should be considered a critical factor in the management of hypertension in renal transplant recipients. Most renal transplant recipients have other risk factors for premature cardiovascular death such as diabetes mellitus, hypercholesterolemia, insulin resistance, obesity, left ventricular hypertrophy and ischaemic heart disease. Initial antihypertensive therapy should be tailored individually according to the patient's risk factors. A realistic therapeutic goal for blood pressure management in the initial postoperative state is a systolic blood pressure < 160 mmHg and a diastolic blood pressure < 90 mmHg with lower pressure targets becoming applicable late post transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0033393848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033393848&partnerID=8YFLogxK

M3 - Article

C2 - 10651388

AN - SCOPUS:0033393848

VL - 58

SP - 1011

EP - 1027

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 6

ER -